Antidepressant studies in Parkinson's disease: A review and meta-analysis

Movement Disorders

Volumn 20, Issue 9, 2005, Pages 1161-1169

  Weintraub, Daniel ^a,b,c   Morales, Knashawn H ^a   Moberg, Paul J ^a,b   Bilker, Warren B ^a   Balderston, Catherine ^a   Duda, John E ^a,b   Katz, Ira R ^a,b   Stern, Matthew B ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c NONE   (United States)

Author keywords

Antidepressive agent; Depression; Effect size; Meta analysis; Parkinson's disease; Treatment

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BROMOCRIPTINE; CITALOPRAM; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MOCLOBEMIDE; NOMIFENSINE; NORTRIPTYLINE; PAROXETINE; PLACEBO; REBOXETINE; S ADENOSYLMETHIONINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGE; AGED; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG RESPONSE; DRUG TOLERABILITY; DRUG USE; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; META ANALYSIS; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; HUMANS; PARKINSON DISEASE;

EID: 27744564717     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.20555     Document Type: Article

References (67)

1. Tandberg E, Larsen JP, Aarsland D, Cummings JL. The occurrence of depression in Parkinson's disease. a community-based study. Arch Neurol 1996;53:175-179.
2. Slaughter JR, Slaughter KA, Nichols D, et al. Prevalence, clinical manifestations, etiology, and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2001;13:187-196.
3. Richard IH, Kurlan R, Parkinson Study Group. A survey of anti-depressant use in Parkinson's disease. Neurology 1997;49:1168-1170.
4. Weintraub D, Moberg PJ, Duda JE, et al. Recognition and treatment of depression in Parkinson's disease. J Geriatr Psychiatry Neurol 2003;16:178-183.
5. Wermuth L, Sørensen PS, Timm S, et al. Depression in idiopathic Parkinson's disease treated with citalopram: a placebo-controlled trial. Nord J Psychiatry 1998;52:163-169.
6. Cummings JL, Masterman DL. Depression in patients with Parkinson's disease. Int J Geriatr Psychiatry 1999;14:711-718.
7. Starkstein SE, Preziosi TJ, Bolduc PL, et al. Depression in Parkinson's disease. J Nerv Ment Dis 1990;178:27-31.
8. Poewe W, Luginger E. Depression in Parkinson's disease. Neurology 1999;52(Suppl.):2-6.
9. Tandberg E, Larsen JP, Aarsland D, et al. Risk factors for depression in Parkinson disease. Arch Neurol 1997;54:625-630.
10. Mayeux R, Stern Y, Williams JBW, et al. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986;143:756-759.
11. Hoogendijk WJ, Sommer IEC, Tissingh G, et al. Depression in Parkinson's disease: the impact of symptom overlap on prevalence. Psychosomatics 1998;39:416-421.
12. Leentjens AF, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depression in Parkinson's disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003;15:74-77.
13. Dreisig H, Beckmann J, Wermuth L, et al. Psychologic effects of structured cognitive psychotherapy in young patients with Parkinson's disease. Nord J Psychiatry 1999;53:217-221.
14. Leentjens AF, Vreeling FW, Luijckx GJ, et al. SSRIs in the treatment of depression in Parkinson's disease. Int J Geriatr Psychiatry 2003;18:552-554.
15. de la Fuente-Fernández R, Stoessl AJ. The placebo effect in Parkinson's disease. Trends Neurosci 2002;25:302-306.
16. Klaassen T, Verhey FR, Sneijders GH, et al. Treatment of depression in Parkinson's disease: a meta-analysis. J Neuropsychiatry Clin Neurosci 1995;7:281-286.
17. Treatment of depression in idiopathic Parkinson's disease. Mov Disord 2002;17(Suppl.):112-119.
18. Chung TH, Deane KH, Ghazi-Noori S, et al. Systematic review of antidepressant therapies in Parkinson's disease. Parkinsonism Relat Disord 2003;10:59-65.
19. Rosenthal R. Meta-analytic procedures for social research. Revised edition. Beverly Hills: Sage Publications; 1984.
20. Rosenthal R. Meta-analytic procedures for social research. Newbury Park, UK: Sage Publications; 1991.
21. Hedges LV, Olkin I. Statistical methods for meta-analysis. New York: Academic Press; 1985.
22. Glass GV. Integrating findings: the meta-analysis of research. Rev Res Educ 1977;5:351.
23. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1977.
24. Rosnow RL, Rosenthal R. Computing contrasts, effect sizes, and counternulls on other people's published data: general procedures for research consumers. Psychol Methods 1996;1:331-340.
25. Cohen J. Statistical power analysis for the behavioral sciences. New York: Academic Press; 1977.
26. Sutton AJ, Abrams KR, Jones DF, et al: Methods for meta-analysis in medical research. New York, NY: John Wiley & Sons; 2000.
27. Borenstein M, Rothstein M. Comprehensive meta-analysis manual. Englewood, NJ: Biostat; 1999.
28. Schneider LS, Nelson JC, Clary CM, et al. An 8-week multicenter, parallel-group, double-blind, placebo-controlled study of sertraline in elderly outpatients with major depression. Am J Psychiatry 2003; 160:1277-1285.
29. Tollefson GD, Bosomworth JC, Heiligenstein JH, et al. A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. Int Psychogeriatr 1995;7:89-104.
30. Allain H, Cougnard J, Neukirch HC, et al. Selegiline in de novo parkinsonian patients: the French selegiline multicenter trial (FSMT). Acta Neurol Scand 1991;84(Suppl.):73-78.
31. Andersen J, Aabro E, Gulmann N, et al. Anti-depressive treatment in Parkinson's disease: a controlled trial of the effect of nortripty-line in patients with Parkinson's disease treated with 1-dopa. Acta Neurol Scand 1980;62:210-219.
32. Aarsland D, Larsen JP, Lim NG, et al. α2-Adrenoreceptor antagonism and serotonin reuptake inhibition in patients with Parkinson's disease and depression. Nord J Psychiatry 2000;54:411-415.
33. Baronti F, Davis TL, Boldry RC, et al. Deprenyl effects on levodopa pharmacodynamics, mood, and free radical scavenging. Neurology 1992;42:541-544.
34. Bedard P, Parkes JD, Marsden CD. Nornifensine in Parkinson's disease. Br J Clin Pharmacol 1977;4(Suppl.): 187-190.
35. Carrieri PB, Indaco A, Gentile S, et al. S-adenosylmethionine treatment of depression in patients with Parkinson's disease. Curr Ther Res 1990;48:154-160.
36. Ceravolo R, Nuti A, Piccinni A, et al. Paroxetine in Parkinson's disease: effects on motor and depressive symptoms. Neurology 2000;55:1216-1218.
37. Dell'Agnello G, Ceravolo R, Nuti A, et al. SSRIs do not worsen Parkinson's disease: evidence from an open-label, prospective study. Clin Neuropharmacol 2001;24:221-227.
38. Di Rocco A, Rogers JD, Brown R, et al. S-Adenosyl-methionine improves depression in patients with Parkinson's disease in an open-label clinical trial. Mov Disord 2000;15:1225-1229.
39. Fischer PA, Baas H. Therapeutic efficacy of R-(-)-deprenyl as adjuvant therapy in advanced parkinsonism. J Neural Transm 1987;25(Suppl): 137-147.
40. Goetz CG, Tanner CM, Klawans HL. Bupropion in Parkinson's disease. Neurology 1984;34:1092-1094.
41. Hauser RA, Zesiewicz TA. Sertraline for the treatment of depression in Parkinson's disease. Mov Disord 1997;12:756-759.
42. Hietanen MH. Selegiline and cognitive function in Parkinson's disease. Acta Neurol Scand 1991;84:407-410.
43. Indaco A, Carrieri PB. Amitriptyline in the treatment of headache in patients with Parkinson's disease. Neurology 1988;38:1720-1722.
44. Jouvent R, Abensour P, Bonnet AM, et al. Antiparkinsonian and antidepressant effects of high doses of bromocriptine: an independent comparison. J Affect Disord 1983;5:141-145.
45. Laitinen L. Desipramine in treatment of Parkinson's disease. Acta Neurol Scand 1969;45:109-113.
46. Lees AJ, Shaw KM, Kohout LJ, et al. Deprenyl in Parkinson's disease. Lancet 1977;2:791-795.
47. Lemke MR. Effect of reboxetine on depression in Parkinson's disease patients. J Clin Psychiatry 2002;63:300-304.
48. Meara RJ, Bhowmick BK, Hobson JP. An open uncontrolled study of the use of sertraline in the treatment of depression in Parkinson's disease. J Serotonin Res 1996;4:243-249.
49. Przuntek H, Kuhn W. The effect of R-(-)-deprenyl in de novo Parkinson patients on combination therapy with levodopa and decarboxylase inhibitor. J Neural Transm 1987;25(Suppl.):97-104.
50. Rampello L, Chiechio S, Raffaele R, et al. The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. Clin Neuropharmacol 2002;25:21-24.
51. Rihmer Z, Sátori M, Pestality P. Selegiline-citalopram combination in patients with Parkinson's disease and major depression. Int J Psychiatry Clin Pract 2000;4:123-125.
52. Steur EN, Ballering LA. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. In: Stern GM, editor. Advances in neurology. Vol. 80. Philadelphia: Lippincott Williams & Wilkins; 1999.
53. Strang RR. Imipramine in treatment of parkinsonism: a double-blind placebo study. Br Med 1 1965;2:33-34.
54. Tesei S, Antonini A, Canesi M, et al. Tolerability of paroxetine in Parkinson's disease: a prospective study. Mov Disord 2000;15: 986-989.
55. Feighner JP, Robins E, Guze SB, et al. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972;26:57-63.
56. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
57. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-389.
58. Sheikh A Yesavage JA. Geriatric Depression Scale (GDS): recent evidence and development of a shorter version. In: Brink TL, editor. Clinical gerontology: a guide to assessment and intervention. New York: The Haworth Press; 1986.
59. Andersen J. Depressive tilstande bedømt ved rating scales. Copenhagen: University of Copenhagen; 1975.
60. Alexopoulos GS, Katz IR, Reynolds CF 3rd, et al. The expert consensus guideline series: pharmacotherapy of depressive disorders in older patients. Postgrad Med 2001;1-86.
61. Zung WW. A self-rating depression scale. Arch Gen Psychiatry 1965; 12:63-70.
62. Beck AT, Ward CH, Mendelson M, et al. An inventory of measuring depression. Arch Gen Psychiatry 1961;4:53-63.
63. McNair DM, Lorr M, Droppleman LF. Profile of mood states. San Diego, CA: Educational and Industrial Testing Service; 1971.
64. Ackermann RT, Williams JW. Rational treatment choices for non-major depressions in primary care: an evidence-based review. J Gen Intem Med 2002;17:293-301.
65. Oxman TE, Sengupta A. Treatment of minor depression. Am J Geriatr Psychiatry 2002;10:256-264.
66. van de Vijver DA, Roos RA, Jansen PA, et al. Start of a selective serotonin reuptake inhibitor (SSRI) and increase of antiparkinsonian drug treatment in patients on levodopa. Br J Clin Pharmacol 2003;54:168-170.
67. Begg C, Cho M, Eastwood S, et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statement. JAMA 1996;276:637-639.